Last reviewed · How we verify
Cycloplegia — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cyclogyl | CYCLOPENTOLATE | Alcon Labs Inc | cyclopentolate | Muscarinic acetylcholine receptor M3 | 1974-01-01 | |
| scopolamin | scopolamin | University Hospital, Angers | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Cycloplegia
- Alcon Labs Inc · 1 drug in Cycloplegia
- University Hospital, Angers · 1 drug in Cycloplegia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cycloplegia:
- Cycloplegia treatment updates — RSS
- Cycloplegia treatment updates — Atom
- Cycloplegia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cycloplegia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cycloplegia. Accessed 2026-06-10.
Related
- Cycloplegia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing